The Antiasthma Medication Ciclesonide Suppresses Breast Cancer Stem Cells through Inhibition of the Glucocorticoid Receptor Signaling-Dependent YAP Pathway
Ciclesonide is an FDA-approved glucocorticoid used to treat asthma and allergic rhinitis. However, whether it has anticancer and anti-cancer stem cell (CSC) effects is unknown. This study focused on investigating the effect of ciclesonide on breast cancer and CSCs and determining its underlying mech...
Main Authors: | Su-Lim Kim, Hack Sun Choi, Ji-Hyang Kim, Dong-Sun Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/24/6028 |
Similar Items
-
Ciclesonide activates glucocorticoid signaling in neonatal rat lung but does not trigger adverse effects in the cortex and cerebellum
by: Juliann D. Jaumotte, et al.
Published: (2021-08-01) -
CICLESONIDE IN TREATMENT OF CHILDHOOD BRONCHIAL ASTHMA
by: K. E. Efendieva, et al.
Published: (2013-02-01) -
Caudatin Isolated from <i>Cynanchum auriculatum</i> Inhibits Breast Cancer Stem Cell Formation via a GR/YAP Signaling
by: Xing Zhen, et al.
Published: (2020-06-01) -
The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation
by: Hack Sun Choi, et al.
Published: (2020-02-01) -
Efficacy of ciclesonide in the treatment of patients
with asthma exacerbation
by: Ziemowit Zietkowski, et al.
Published: (2019-05-01)